235 related articles for article (PubMed ID: 31172849)
1. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
Comi G; Miller AE; Benamor M; Truffinet P; Poole EM; Freedman MS
Mult Scler; 2020 Aug; 26(9):1083-1092. PubMed ID: 31172849
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
4. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
Qiu W; Huang DH; Hou SF; Zhang MN; Jin T; Dong HQ; Peng H; Zhang CD; Zhao G; Huang YN; Zhou D; Wu WP; Wang BJ; Li JM; Zhang XH; Cheng Y; Li HF; Li L; Lu CZ; Zhang X; Bu BT; Dong WL; Fan DS; Hu XQ; Xu XH;
Chin Med J (Engl); 2018 Dec; 131(23):2776-2784. PubMed ID: 30511679
[TBL] [Abstract][Full Text] [Related]
7. Teriflunomide in multiple sclerosis: an update.
Miller AE
Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
[TBL] [Abstract][Full Text] [Related]
8. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Chan A; de Seze J; Comabella M
CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS;
Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
Miller AE; Olsson TP; Wolinsky JS; Comi G; Kappos L; Hu X; Xu X; Lublin AL; Truffinet P; Chavin J; Delhay JL; Benamor M; Purvis A; Freedman MS;
Mult Scler Relat Disord; 2020 Nov; 46():102438. PubMed ID: 32911306
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Scott LJ
Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
17. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M
Mult Scler; 2024 Jun; 30(7):833-842. PubMed ID: 38619037
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide for the treatment of multiple sclerosis.
Warnke C; Stüve O; Kieseier BC
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
